 | Up a level |
Journal Article
Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Tan, D. S., Kim, S-W., Sequist, L. V., Ponce Aix, S., Smit, E. F., Hida, T., Yang, J. C-H., Felip, E., Seto, T., Grohe, C., Wolf, J., Ko, J., Marriere, E., Belli, R., Giovannini, M. and Kim, D-W. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann. Oncol., 29. S. 748 - 749. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041